医学院
|
|
|
|
导师代码: |
20107
|
导师姓名: |
钟磊
|
性 别: |
男 |
特 称: |
|
职 称: |
副教授
|
学 位: |
理学博士学位
|
属 性: |
专职 |
电子邮件: |
zhl7235301@163.com
|
|
|
学术经历:
|
|
2015年07月-2019年03月,电子科技大学附属医院·四川省人民医院,助理研究员;
2015年10月-2018年12月,四川大学,生物学,博士后(在职);
2017年01月-2021年10月,电子科技大学医学院,讲师;
2019年04月-至今,电子科技大学附属医院·四川省人民医院,副研究员;
2021年11月-至今,电子科技大学医学院,副教授;
2022年06月-2023年05月,瑞典乌普萨拉大学访问学者。
|
|
个人简介:
|
|
钟磊,博士,副教授/副研究员,硕士生导师,四川省卫健委第十四批学术技术带头人后备人选,四川省抗癌协会肿瘤临床药学专委会委员,四川省药理学学会治疗药物监测研究专委会委员兼秘书。2012年7月毕业于四川大学华西药学院药剂学专业,获理学硕士学位;2015年6月毕业于四川大学生物治疗国家重点实验室化学生物学专业,获理学博士学位;2015年7月入职电子科技大学附属医院·四川省人民医院,主要从事肿瘤药理学和药物基因组学方向的教学、科研工作,在小分子抗肿瘤靶向药物研发、肿瘤耐药机制及药物基因组学研究方面具有丰富经验。
|
|
科研项目:
|
|
近年来主持包括国家自然科学基金项目(81702286),中国博士后面上项目(2016M592677),四川省科技厅项目(2021YJ0134,2017YSKY0001),四川省卫健卫课题(16PJ483),成都市科技局项目(2022-YF05-01611-SN),电子科技大学中央高校基金、四川省人民医院青年人才基金(2016QN11),以及吴阶平基金等各级科研项目10余项。
|
|
研究成果:
|
|
发表学术论文40余篇,其中,以一作或通讯作者身份发表SCI论文近20篇;作为项目参与人获四川省医学科技一等奖和二等奖各1项。
1. Yue Tong, et al. Photocatalytic redox-neutral arylation of cyclopropanols with cyanoarenes via radicalmediated C–C and C–CN bond cleavage. Org. Chem. Front., 2022, 9: 2129-2134. (通讯作者)
2. Xuerun Peng, et al. Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges. Drug Des Devel Ther, 2022, 16:2639-2657. (通讯作者)
3. Zhong Lei, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. SIGNAL TRANSDUCTION AND TARGETED THERAPY,2021,6(1): 201.
4. Xuerun Peng, et al. Targeting H3K36 methyltransferases NSDs: a promising strategy for tumor targeted therapy.SIGNAL TRANSDUCTION AND TARGETED THERAPY,2021,6(1): 220. (通讯作者)
5. Zhenyu Yang, et al. Discovery of BAZ1A bromodomain inhibitors with the aid of virtual screening and activity evaluation. Bioorg Med Chem Lett, 2021,33: 127745. (通讯作者)
6. Lingyu Su, et al. Anti-oral squamous cell carcinoma effects of a potent TAZ inhibitor AR-42. Journal of Cancer, 2020, 11(2): 364-373. (通讯作者)
7. Qian Peng , et al. Association of elevated Yes-associated protein expression with gastric cancer and its clinicopathological features. J Biosci Med, 2020, 8, 96-109. (通讯作者)
8. Zhong Lei, et al. Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma. Investigational New Drugs, 2019, 37: 616-624.
9. Yanping Zhou, et al. Design, synthesis and in vitro tumor cytotoxicity evaluation of 3,5-diamino-N-substituted benzamide derivatives as novel GSK-3β small molecule inhibitors. Chem. Biodiversity, 2019, 16: e1900304. (通讯作者)
10. Yuxuan Zhu, et al. AR-42: A pan-HDAC inhibitor with antitumor and antiangiogenic activities in esophageal squamous cell carcinoma. DRUG DESIGN DEVELOPMENT AND THERAPY,2019,13: 4321-4330.(通讯作者)
11.Zhong Lei, et al. Protective effect of ethyl vanillin against Aβ induced neurotoxicity in PC12 cells via the reduction of oxidative stress and apoptosis Experimental and Therapeutic Medicine, 2019, 17: 2666-2674.
12.Zhong Lei, et al. Relevance of methylenetetrahydrofolate reductase gene variants C677T and A1298C with response to fluoropyrimidinebased chemotherapy in colorectal cancer: a systematic review and meta-analysis. Oncotarget, 2018, 9 (58): 31291-31301.
13.Yang Ling-Ling#, Wang Hua-Li#, Zhong Lei#, et al. X-ray crystal structure guided discovery of new selective, substratemimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells. European Journal of Medicinal Chemistry, 2018, 155: 806-823.
14.Zhong Lei, et al. Relevance of MTHFR polymorphisms with response to floropyrimidine based chemotherapy in oesophagogastric cancer: a meta-analysis. BMJ Open, 2018, 8: e020767.
15.Zhong Lei, et al. Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer. Oncotarget, 2017, 8 (8): 12843-12854.
16.Zhong Lei, et al. A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma. International Journal of Cancer, 2014, 135 (12): 2972-2983.
17.Zhong Lei, Ma Chang-Ying, Zhang Hui, Yang Li-Jun, Wan Hua-Lin, Xie Qing-Qing, Li Lin-Li, Yang Sheng-Yong*. A prediction model of substrates and non-substrates of breast cancer Resistance protein (BCRP) developed by GA–CG –SVM method. Computers in Biology and Medicine, 2011, 41 (11): 1006-1013.
|
|
专业研究方向:
|
专业名称 |
研究方向 |
招生类别 |
105500药学 |
02药物研究与转化 |
硕士专业学位 |
|
|
|
|
|
|
|